DOM-ATORVASTATIN TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
13-09-2018
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ATORVASTATIN (ATORVASTATIN CALCIUM)
Inapatikana kutoka:
DOMINION PHARMACAL
ATC kanuni:
C10AA05
INN (Jina la Kimataifa):
ATORVASTATIN
Kipimo:
40MG
Dawa fomu:
TABLET
Tungo:
ATORVASTATIN (ATORVASTATIN CALCIUM) 40MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
500
Dawa ya aina:
Prescription
Eneo la matibabu:
HMG-COA REDUCTASE INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0133055003; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2012-01-10
Tabia za bidhaa
_ _
PRODUCT MONOGRAPH
PR
DOM-ATORVASTATIN
(atorvastatin calcium tablets)
10 mg, 20 mg, 40 mg and 80 mg atorvastatin
LIPID METABOLISM REGULATOR
DOMINION PHARMACAL
Date of Revision:
6111 Royalmount Ave., Suite #100
September 13, 2018
Montréal, Québec
H4P 2T4
Submission Control No.: 219990
_Dom-ATORVASTATIN Product Monograph _
_ _
_Page 2 of 49 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
....................................................................................
18
OVERDOSAGE
.......................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 20
STORAGE AND STABILITY
................................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL INFORMATION
...................................
Soma hati kamili
